This notion is exemplified in CD133+ CSCs in glioblastoma and pancreatic adenocarcinoma, low reactive oxygen species quiescent stem cells in leukemia, and side population of lung and breast cancer[83]. This evidence concerns the gene PROM1 and breast carcinoma.